今年第18届圣加伦（SG）关于早期乳腺癌治疗的共识会议（SGBCC：圣加伦国际乳腺癌会议）的重点是以实践为导向的问题。详细讨论了个人情况和风险收益评估。和往年一样,一个由领先的乳腺癌专家组成的德国工作组在德国治疗建议的背景下介绍了2023年国际SGBCC的结果-特别是ArbeitsgemeinschaftGynäkologischee.V.（AGO）的最新治疗建议-用于德国的日常临床实践。德国AGO的治疗建议是基于目前的证据。与德国的临床方法进行比较已被证明是有用的，SGBCC小组由来自不同国家和学科的专家组成。这就是为什么可以将特定国家的特征纳入SGBCC建议的原因。
This year\'s 18th St. Gallen (SG)
consensus conference on the treatment of early breast cancer (SGBCC: St. Gallen International Breast Cancer Conference) focused on practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As in previous years, a German working group of leading breast cancer experts presented the results of the international SGBCC 2023 against the background of German treatment recommendations - especially the updated treatment recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) - for everyday clinical practice in Germany. The German treatment recommendations of AGO are based on the current evidence. The comparison with the clinical approach in Germany has proven useful, as the SGBCC panel consists of experts from different countries and disciplines. That is why country-specific characteristics can be incorporated into the SGBCC recommendations.
PDF(Pubmed)